Skip to main content
Premium Trial:

Request an Annual Quote

Biocept, MD Anderson Expand Ovarian Cancer Collaboration

NEW YORK (GenomeWeb) — Biocept said today that it has expanded its collaboration with the University of Texas MD Anderson Cancer Center in the area of ovarian cancer.

San Diego-based Biocept specializes in the analysis of biomarkers in cell-free circulating tumor DNA and circulating tumor cells. The expansion of its collaboration with MD Anderson follows findings from a recent study in which MD Anderson researchers successfully used Biocept's OncoCEE platform in a mouse model of ovarian cancer. The results of the study were published in July in Cancer Cell.

The OncoCEE microfluidic device captures CTCs then evaluates the expression of the genomic marker HER3 (human epidermal growth factor 3) in ovarian cancer cells to provide insight into alternative routes of metastasis, Biocept said. According to a company spokesperson, Biocept and MD Anderson had previously collaborated on breast cancer studies.

In a statement, Biocept President and CEO Michael Nall said that Biocept believes the findings from the recently published study are valuable "as they help in our understanding of ovarian cancer metastasis and how to improve clinical management of these patients." He added that "partnerships with top-tier centers such as [MD Anderson] are a pillar of our growth strategy and we will continue to work to further develop our relationships with academic and research partners."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.